Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 17/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13164128 | 0.78 | ALDH1A1 (0.57) | MEN1ALDH1A1POLBKMT2ATDP1 | |
| SCHEMBL15685943 | 0.76 | ALDH1A1 (0.74) | MEN1ALDH1A1POLBKMT2ATDP1 | |
| SCHEMBL5307911 | 0.76 | KDM4E (0.74) | MEN1ALDH1A1POLBKMT2ATDP1 | |
| SCHEMBL13126362 | 0.74 | MAPK8 (1.00) | MAPK8MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10035809 | 0.74 | ALDH1A1 (0.64) | MEN1ALDH1A1POLBKMT2ATDP1 | |
| SCHEMBL2207637 | 0.74 | MAPT (0.63) | ALDH1A1POLBTDP1HTTNPC1 | |
| SCHEMBL30343700 | 0.74 | MAPT (0.63) | ALDH1A1POLBTDP1HTTNPC1 | |
| SCHEMBL12409534 | 0.73 | ALDH1A1 (0.67) | MEN1ALDH1A1POLBKMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL2211742 | 0.72 | ALDH1A1 (0.66) | ALDH1A1POLBTDP1HTTNPC1 | |
| SCHEMBL8635361 | 0.71 | ALDH1A1 (0.57) | MEN1ALDH1A1POLBKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240720-A1 | ALLOSTERIC JNK INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240720-A1 | ALLOSTERIC JNK INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240720-A1 | ALLOSTERIC JNK INHIBITORS | MCL1, MAPKAPK2, MAP3K6 | MAPK8 21/4885MEN1 3413/4885ALDH1A1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.